[Studies of monocytopoiesis in patients with malignant disease and after immunostimulation with BCG, using 3H-thymidine as a DNA-label (author's transl)].
Monocytopoiesis and blood monocytes were investigated in patients with Hodgkin's disease, non-Hodgkin lymphomas, mycosis fungoides, breast cancer or melanoma. The investigation was carried out before surgery and just before each application of BCG. Monocyte production was increased in untreated patients. Postoperative prophylactic BCG-vaccination gave rise to increased proliferation activity. However monocyte production returned to normal between the 4th and 6th month of BCG immunotherapy. These results indicate that monocytopoiesis is stimulated by human tumors. BCG immunostimulation is able to increase proliferation activity during the first month of treatment only.
D001500:BCG Vaccine / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006689:Hodgkin Disease / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008223:Lymphoma / Q000503:physiopathology / Q000628:therapy; D008545:Melanoma / Q000503:physiopathology / Q000628:therapy; D009000:Monocytes / Q000276:immunology; D009182:Mycosis Fungoides / Q000503:physiopathology / Q000628:therapy; D009369:Neoplasms / Q000503:physiopathology*
D001500:BCG Vaccine
Untersuchungen zur Monozytopoese bei malignen Erkrankungen und unter BCG-Immunstimulation mit Hilfe des DNA-Markers 3H-Thymidin.